About
Fertiga develops the Aurora niPCT™, a non-invasive molecular test analyzing cumulus cells removed during ICSI to rank egg quality and improve embryo selection in IVF, thereby increasing pregnancy and live birth rates.
Explore Fertiga's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.